An interventional study of True Foot Reflexology and Sham Foot Reflexology in Head and Neck Neoplasms, Xerostomia and Cancer-related Fatigue, sponsored by Tzu Chi University. Recruiting at 1 site in Taiwan. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Tzu Chi University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Head and Neck Neoplasms with a site in Taiwan — 24 open to participants now, 40 under way, 8 of them phase 3. Head and Neck Neoplasms · Taiwan.
Among the 118 studies in Head and Neck Neoplasms with a site in Taiwan, this one is the 34th largest by planned enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2026, is one of 28 with no phase, reaches primary completion later than 32 of the 39 other live ones, and was the 118th registered.
2,717 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.
Browse Head and Neck Neoplasms studies →24 of the 118 studies in Head and Neck Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:
EpiBiologics · Sites in Taiwan, United States, Korea, Republic of
Ages 18+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18 mo–90 yrs · Healthy volunteers
China Medical University Hospital · Sites in Taiwan
Ages 18–80
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18+ · Healthy volunteers
Bicara Therapeutics · Sites in Taiwan, United States, Argentina and 25 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 22 · Phase 4 3
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 46 across 2,036 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 110 across the 95 interventional studies, 139 across the 23 observational. Of the 59 that completed or were terminated, 23 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 118 have an industry lead sponsor. The 10 most frequent:
Tzu Chi University is the lead sponsor of 20 studies on the registry; 4 are open to participants now.
Tzu Chi University has 1 study filed under Head and Neck Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Head and Neck Neoplasms with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07293013Chiayi Christian HospitalA Study on the Effectiveness of Olive Oil Mouthwash in Alleviating Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer. | 2026-12 |
| NCT07435415China Medical University HospitalLocal Injection Methylene Blue Combined With Radiation in HNSCC Patients | 2026-12-31 |
| NCT07252557Chung Shan Medical UniversityMouthwash Temperature and Oral Mucositis in Head and Neck Radiotherapy | 2026-12-31 |
| NCT07689019Buddhist Tzu Chi General HospitalEffects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short Term Prognosis of Head and Neck Cancer Patients Receiving Curative Treatment | 2026-12-31 |
| NCT06666881Chang Gung Memorial HospitalSkeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in HNSCC Patients | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 118 studies in Head and Neck Neoplasms with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Head and neck cancer (HNC) patients undergoing concurrent chemoradiotherapy (CCRT) frequently experience pain, xerostomia, fatigue, sleep disturbance, and other treatment-related toxicities that impair quality of life and treatment adherence, with incomplete relief from current supportive care. This randomized, single-blind, sham-controlled trial evaluates whether foot reflexology (FR), transcutaneous auricular vagus nerve stimulation (ta-VNS), and auricular acupressure (AA) reduce pain, xerostomia, fatigue, sleep disturbance, and treatment-related symptoms in HNC patients receiving cisplatin-based CCRT, compared with usual care. Participants are randomized to a foot reflexology group, an auricular vagus nerve stimulation group (each with true and sham subgroups), or a usual-care control group, and are followed at baseline and weeks 1, 2, and 4.
This is a three-arm parallel, repeated-measures randomized controlled trial conducted in the otolaryngology outpatient and inpatient settings of Hualien Tzu Chi Hospital. Eligible patients with pathologically confirmed HNC (clinical stage II-IVA) scheduled to receive a second cycle of cisplatin-based CCRT are stratified by CRT dose (\<66 Gy vs ≥66 Gy) and randomized using a computer-generated sequence with block size 4 or 8, in a 1:1:1 ratio, to the FR group, the ta-VNS group, or the usual-care control group; the FR and ta-VNS groups are further randomized to true or sham subgroups. The foot reflexology intervention is delivered twice weekly for 20 minutes over two weeks and comprises a relaxation phase, a head-neck/gastrointestinal regulation phase, and a circulation/detoxification phase; the sham condition applies light, non-specific touch. The ta-VNS intervention stimulates the left tragus, cymba conchae, and cavum conchae (pulse width 250 µs, 25 Hz, 0.5-5 mA individualized to a tingling sensation, 30 s on/off) twice weekly for 20 minutes over two weeks; the sham condition stimulates the left earlobe at 0.5 mA. Auricular acupressure with magnetic beads is self-administered three times daily. Outcomes are assessed at T0 (baseline), T1 (week 1), T2 (week 2), and T3 (week 4). Data are analyzed with generalized estimating equation (GEE) models.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: True Foot Reflexology
Procedure: True Foot Reflexology
Procedure: Sham Foot Reflexology
Procedure: Sham Foot Reflexology
Device: True ta-VNS + Procedure: Auricular Acupressure
Device: True ta-VNS · Procedure: True Auricular Acupressure
Device: Sham ta-VNS + Procedure: Sham Auricular Acupressure
Device: Sham ta-VNS · Procedure: Sham Auricular Acupressure
Other: Usual Care
Other: Usual Care
Twice weekly, 20 min, over 2 weeks. Three phases: relaxation (diaphragm, brain, spine zones, 3 min); head-neck function and gastrointestinal regulation (upper/lower GI, thyroid, adrenal zones, 10 min); circulation/detoxification (kidney, lymphatic zones, 7 min).
Light touch on non-specific foot areas without
Left tragus, cymba conchae, cavum conchae; 250 µs, 25 Hz, 0.5-5 mA individualized to tingling, 30 s on/off; twice weekly, 20 min, 2 weeks. Device: Hong-Tai mid-frequency electrotherapy stimulator, model HT66B (TFDA license no. 000637), used off-label for auricular vagus nerve stimulation.
Left earlobe, 0.5 mA, otherwise identical parameters.
Magnetic beads (1-2 mm) at left tragus, cymba conchae, cavum conchae; 3×/day, \~30 s per point; changed every 2-3 days.
Beads at left earlobe (non-vagal regions), same frequency/duration.
Standard CCRT nursing care, antiemetic medication, side-effect prevention education, and symptom monitoring; no study intervention.
Change in Numeric Rating Scale (NRS) for pain
0-10 scale; 0 = no pain, 10 = worst pain.
Time frame: T0 baseline, T1 week 1, T2 week 2, T3 week 4
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.
Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 29 months is below that.
Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tzu Chi University